|
Neoplasia
Citations 71-80 of 4217 total displayed.
|
Past content
(since Jan 1997):
|
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
- Ken H. Young, Karen Leroy, Michael B. Møller, Gisele W. B. Colleoni, Margarita Sánchez-Beato, Fábio R. Kerbauy, Corinne Haioun, Jens C. Eickhoff, Allen H. Young, Philippe Gaulard, Miguel A. Piris, Terry D. Oberley, William M. Rehrauer, Brad S. Kahl, James S. Malter, Elias Campo, Jan Delabie, Randy D. Gascoyne, Andreas Rosenwald, Lisa Rimsza, James Huang, Rita M. Braziel, Elaine S. Jaffe, Wyndham H. Wilson, Louis M. Staudt, Julie M. Vose, Wing C. Chan, Dennis D. Weisenburger, and Timothy C. Greiner
Blood 2008; 112: 3088-3098.
[Abstract]
[Full text]
[PDF]
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- Antonio Palumbo, Sara Bringhen, Anna M. Liberati, Tommaso Caravita, Antonietta Falcone, Vincenzo Callea, Marco Montanaro, Roberto Ria, Antonio Capaldi, Renato Zambello, Giulia Benevolo, Daniele Derudas, Fausto Dore, Federica Cavallo, Francesca Gay, Patrizia Falco, Giovannino Ciccone, Pellegrino Musto, Michele Cavo, and Mario Boccadoro
Blood 2008; 112: 3107-3114.
[Abstract]
[Full text]
[PDF]
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, and John Crowley
Blood 2008; 112: 3115-3121.
[Abstract]
[Full text]
[PDF]
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
- Derville O'Shea, Ciarán O'Riain, Claire Taylor, Rachel Waters, Emanuela Carlotti, Finlay MacDougall, John Gribben, Andreas Rosenwald, German Ott, Lisa M. Rimsza, Erlend B. Smeland, Nathalie Johnson, Elias Campo, Timothy C. Greiner, Wing C. Chan, Randy D. Gascoyne, George Wright, Louis M. Staudt, T. Andrew Lister, and Jude Fitzgibbon
Blood 2008; 112: 3126-3129.
[Abstract]
[Full text]
[PDF]
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
- Miguel A. Sanz, Pau Montesinos, Edo Vellenga, Consuelo Rayón, Javier de la Serna, Ricardo Parody, Juan M. Bergua, Angel León, Silvia Negri, Marcos González, Concha Rivas, Jordi Esteve, Gustavo Milone, José D. González, Elena Amutio, Salut Brunet, J. García-Laraña, Dolors Colomer, María J. Calasanz, Carmen Chillón, Eva Barragán, Pascual Bolufer, and Bob Lowenberg
Blood 2008; 112: 3130-3134.
[Abstract]
[Full text]
[PDF]
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
- Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro M. Vannucchi, Federica Delaini, Vittoria Guerini, Marco Ruggeri, Francesco Rodeghiero, Alessandro Rambaldi, and Tiziano Barbui
Blood 2008; 112: 3135-3137.
[Abstract]
[Full text]
[PDF]
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
- Claudia Stolz, Georg Hess, Patricia S. Hähnel, Florian Grabellus, Sandra Hoffarth, Kurt W. Schmid, and Martin Schuler
Blood 2008; 112: 3312-3321.
[Abstract]
[Full text]
[PDF]
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- Thorsten Zenz, Alexander Kröber, Katrin Scherer, Sonja Häbe, Andreas Bühler, Axel Benner, Tina Denzel, Dirk Winkler, Jennifer Edelmann, Carsten Schwänen, Hartmut Döhner, and Stephan Stilgenbauer
Blood 2008; 112: 3322-3329.
[Abstract]
[Full text]
[PDF]
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- Susan Branford, Linda Fletcher, Nicholas C. P. Cross, Martin C. Müller, Andreas Hochhaus, Dong-Wook Kim, Jerald P. Radich, Giuseppe Saglio, Fabrizio Pane, Suzanne Kamel-Reid, Y. Lynn Wang, Richard D. Press, Kevin Lynch, Zbigniew Rudzki, John M. Goldman, and Timothy Hughes
Blood 2008; 112: 3330-3338.
[Abstract]
[Full text]
[PDF]
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3
- Björn Lamprecht, Stephan Kreher, Ioannis Anagnostopoulos, Korinna Jöhrens, Giovanni Monteleone, Franziska Jundt, Harald Stein, Martin Janz, Bernd Dörken, and Stephan Mathas
Blood 2008; 112: 3339-3347.
[Abstract]
[Full text]
[PDF]
|
|
